The pH dependence of quantitative ristocetin-induced platelet aggregation: theoretical and practical implications-a new device for maintenance of platelet-rich plasma pH
- PMID: 4176
The pH dependence of quantitative ristocetin-induced platelet aggregation: theoretical and practical implications-a new device for maintenance of platelet-rich plasma pH
Abstract
Quantitative ristocetin-induced platelet aggregation of normal platelet-rich plasma (PRP) decreased with time after PRP preparation. An increase in p H of the PRP with time proved to be responsible for this finding. Diffusion of CO2from the plasma is the prime determinant of the change in pH. Since a complex combination of factors influences CO2 diffusion (surface area-to-volume relationship, capping, mixing, etc.) The change in pH is variable with time. Thus, quantitative ristocetin aggregation should be pH controlled. A simple device for maintaining PRP pH constant by control of the ambient pCO2 was designed and found effective in keeping both pH and quantitative ristocetin aggregation constant over a prolonged period of time. It can be adapted for use in platelet aggregation studies employing other reagents. The pH dependence of ristocetin-induced platelet aggregation is consistent with other data supporting an elctrostatic interaction between the platelet, von Willebrand factor, and ristocetin. We favor a model wherein ristocetin neutralizes some of the platelet's negative change and permits the von Willebrand factor to bridge sites on separate platelets to induce agglutination.
Similar articles
-
Studies on the mechanism of ristocetin-induced platelet agglutination. Effects of structural modification of ristocetin and vancomycin.J Clin Invest. 1977 Aug;60(2):302-12. doi: 10.1172/JCI108778. J Clin Invest. 1977. PMID: 17620 Free PMC article.
-
Proceedings: Variations in quantitative ristocetin platelet aggregation (RPA) with time after platelet rich plasma (PRP) preparation: association with alteration in pH.Thromb Diath Haemorrh. 1975 Nov 15;34(2):581-2. Thromb Diath Haemorrh. 1975. PMID: 809 No abstract available.
-
Plasma and platelet von Willebrand factor defects in uremia.Am J Med. 1988 Dec;85(6):806-10. doi: 10.1016/s0002-9343(88)80025-1. Am J Med. 1988. PMID: 3264111
-
A new von Willebrand variant (type I, New York): increased ristocetin-induced platelet aggregation and plasma von Willebrand factor containing the full range of multimers.Blood. 1986 Jul;68(1):149-56. Blood. 1986. PMID: 3487353
-
Platelet-collagen interaction: inhibition by ristocetin and enhancement by von Willebrand factor-platelet binding.Blood. 1986 Oct;68(4):927-37. Blood. 1986. PMID: 3489493
Cited by
-
A new murine monoclonal antibody reports an activation-dependent change in the conformation and/or microenvironment of the platelet glycoprotein IIb/IIIa complex.J Clin Invest. 1985 Jul;76(1):101-8. doi: 10.1172/JCI111931. J Clin Invest. 1985. PMID: 2991335 Free PMC article.
-
The role of platelet aggregation and release in fragment D-induced pulmonary dysfunction.Ann Surg. 1980 Jul;192(1):103-7. doi: 10.1097/00000658-198007000-00017. Ann Surg. 1980. PMID: 7406554 Free PMC article.
-
Studies on the mechanism of ristocetin-induced platelet agglutination. Effects of structural modification of ristocetin and vancomycin.J Clin Invest. 1977 Aug;60(2):302-12. doi: 10.1172/JCI108778. J Clin Invest. 1977. PMID: 17620 Free PMC article.
-
The platelet: life on the razor's edge between hemorrhage and thrombosis.Transfusion. 2014 Sep;54(9):2137-46. doi: 10.1111/trf.12806. Epub 2014 Aug 5. Transfusion. 2014. PMID: 25092268 Free PMC article. No abstract available.
-
Demonstration and characterization of specific binding sites for factor VIII/von Willebrand factor on human platelets.J Clin Invest. 1979 Apr;63(4):656-64. doi: 10.1172/JCI109348. J Clin Invest. 1979. PMID: 108291 Free PMC article.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Research Materials